Identification of a human heavy chain antibody fragment directed against human platelet alloantigen la by phage display library
Autor: | N Okamoto, Thomas S. Kickler, James F. Casella, Hidetoshi Inoko, Emily Barron-Casella, S. D. Kennedy |
---|---|
Rok vydání: | 2008 |
Předmět: |
endocrine system
Phage display Heavy-chain antibody Immunology General Medicine Biology medicine.disease Biochemistry Virology Molecular biology law.invention Antigen law Neonatal alloimmune thrombocytopenia Genetics medicine biology.protein Recombinant DNA Immunology and Allergy Hybridoma technology Platelet lysate Antibody hormones hormone substitutes and hormone antagonists |
Zdroj: | Tissue Antigens. 51:156-163 |
ISSN: | 0001-2815 |
DOI: | 10.1111/j.1399-0039.1998.tb02960.x |
Popis: | The human platelet alloantigen HPA-1a (PlA1) is responsible for most cases of post-transfusion purpura and neonatal alloimmune thrombocytopenia in the Caucasian population. HPA-1a and HPA-1b are two allelic forms of the platelet membrane glycoprotein IIIa (GPIIIa) gene that differ by a single amino acid. In this report, we describe the development of a recombinant heavy chain antibody fragment capable of distinguishing between the homozygous forms of HPA-1a and HPA-1b. This antibody fragment was isolated from the lymphocytes of an immunized individual through the use of a phage display library system. The recombinant antibody fragment reacted with human platelet lysates from HPA-1a homozygous donors, the HPA-1a form of recombinant N-terminal GPIIIa and intact HPA-1a platelets, but did not react with platelet lysate from HPA-1b homozygous donors, reduced HPA-1a form of platelet GPIIIa or other platelet glycoproteins. This HPA-1a specific human antibody fragment works well in common laboratory assays such as ELISA and flow cytometry, which can assist in identifying HPA-1b homozygous individuals who are known to have a higher risk for developing neonatal alloimmmune thrombocytopenia and post-transfusion purpura. Thus, selection of recombinant antibody fragment using phage display offers a promising alternative to hybridoma technology for the production of human antibodies against human alloantigens and holds potential as a technique in therapeutic applications. |
Databáze: | OpenAIRE |
Externí odkaz: |